Georgia, other states, reach settlement with Bristol-Myers Squibb

[private]Georgia Attorney General Chris Carr has joined with counterparts from 42 other states in a $19.5 million settlement with drug giant Bristol-Myers Squibb Co. (BMS) over allegations of improper marketing of the drug Abilify.

Abilify, the brand name for the anti-psychotic drug aripiprazole, was approved by the U.S. Food and Drug Administration (FDA) in 2002 for the treatment of schizophrenia.

The complaint filed by the attorneys-general alleges that BMS promoted Abilify for use in treating elderly patients with symptoms of dementia and Alzheimer’s disease without FDA approval and without first establishing the drug’s safety and efficacy for those uses.

The complaint also charged that BMS overstated the findings of scientific studies by not revealing limitations that would affect the interpretation of the study results.

“Bristol-Myers Squibb’s alleged deceptive marketing practices potentially endangered the health of Georgia’s most vulnerable populations – seniors and children,” Carr said. “This settlement sends a strong message that Georgia will not tolerate misleading practices that put Georgians at risk.”

© 2016 by The Georgia Report


Tags: Bristol-Myers Squibb , Chris Carr , settlement